The Influence of Antireflux Surgery on Esophageal Cancer Risk in England: National Population-based Cohort Study. by Markar, SR et al.
  
1 
1 
THE INFLUENCE OF ANTI-REFLUX SURGERY ON ESOPHAGEAL CANCER RISK IN ENGLAND – 
NATIONAL POPULATION-BASED COHORT STUDY 
Sheraz R. Markar (PhD)1, Chanpreet Arhi (MRCS)1, Astrid Leusink (MBBS)1, Alberto Vidal-Diez 
(PhD)1,2, Alan Karthikesalingam (PhD)2, Ara Darzi (FRS)1, Jesper Lagergren (PhD)3,4, George B. 
Hanna (PhD)1 
1 – Department of Surgery & Cancer, Imperial College London, UK.  
2 – Molecular and Clinical Sciences Institute, St George’s University of London, Cranmer 
Terrace, London SW17 0RE, UK 
3 – School of Cancer and Pharmaceutical Sciences, King’s College London, UK. 
4 – Department of Molecular Medicine and Surgery, Karolinska Institutet, Sweden.  
Address for Correspondence:  
George B. Hanna  
Division of Surgery,  
Department of Surgery and Cancer,  
Imperial College London,  
10th Floor QEQM Building,  
St Mary’s Hospital,  
South Wharf Road, 
 London, W2 1NY UK 
 
E-mail: g.hanna@imperial.ac.uk  
Telephone No: +44 (0)207 886 2125  Fax No: +44 (0)207 8862125 
Article category: Original article 
Funding: Sheraz R. Markar is funded by the National Institute of Health Research (NIHR). The 
views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the 
Department of Health 
Conflicts of Interests: The authors declared no conflict of interest 
  
2 
2 
Word Count: 2315  Tables: 2 Figures: 3  
Presentation: European Surgical Association 2018 
  
3 
3 
MINI-ABSTRACT 
Anti-reflux surgery is used for the treatment of gastro-esophageal reflux disease, a major risk 
factor for esophageal cancer. This English national population-based cohort study suggested 
anti-reflux surgery is associated with reduced risk of esophageal cancer in patients with gastro-
esophageal reflux disease or Barrett’s esophagus.   
Word count: 44 
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STRUCTURED ABSTRACT 
Objective: To evaluate how anti-reflux surgery influences the risk of esophageal cancer in 
patients with gastroesophageal reflux disease (GERD) and Barrett’s esophagus.  
Background: GERD is a major risk factor for esophageal adenocarcinoma, and the United 
Kingdom has the highest incidence of esophageal adenocarcinoma globally. 
Methods: Hospital Episode Statistics (HES) database was used to identify all patients in England 
aged over 18 years diagnosed with GERD with or without Barrett’s Esophagus from 2000 to 
2012, with anti-reflux surgery being the exposure investigated. The Clinical Practice Research 
Datalink (CPRD) was used to provide a sensitivity analysis comparing proton pump inhibitor 
therapy and anti-reflux surgery. Hazard ratios (HR) with 95% confidence intervals (CI) were 
calculated using Cox proportional hazards model with inverse probability weights based on the 
probability of having surgery to adjust for selection bias and confounding factors. 
Results: (i) HES analysis; among 838,755 included patients with GERD and 28,372 with Barrett’s 
esophagus, 22,231 and 737 underwent anti-reflux surgery, respectively. In GERD patients, anti-
reflux surgery reduced the risk of esophageal cancer (HR=0.64; 95%CI 0.52–0.78). In Barrett’s 
esophagus patients, the corresponding HR was (HR=0.47; 95%CI 0.12–1.90).    
(ii) CPRD analysis; anti-reflux surgery was associated with decreased point estimates of 
esophageal adenocarcinoma in patients with GERD (0% vs. 0.2%; P=0.16) and Barrett’s 
esophagus (HR=0.75; 95%CI 0.21–2.63), but these were not statistically significant.  
Conclusion: Anti-reflux surgery may be associated with a reduced risk of esophageal cancer risk, 
however it remains primarily an operation for symptomatic relief.   
Word count: 243 
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INTRODUCTION 
Esophageal cancer remains in the top five most rapidly rising cancer types in the Western 
world, [1–3] and the UK has the highest incidence of esophageal adenocarcinoma globally [4]. 
Many patients present with advanced disease with only 38% of cases able to be treated with a 
curative intent [5]. Gastroesophageal reflux disease (GERD) is a major risk factor for esophageal 
adenocarcinoma, with recurrent symptomatic GERD leading to an eight-fold increased risk [6]. 
The mechanism of the neoplastic process is GERD leading to oesophagitis and metaplastic 
change in the squamous esophageal epithelium to Barrett’s esophagus and progression with 
dysplastic changes and then eventually to esophageal adenocarcinoma [7,8].  
 
The mainstay of treatment for GERD is medical with proton pump inhibitors (or H2 antagonists), 
but anti-reflux surgery is an alternative, usually performed as a laparoscopic partial or total 
fundoplication [9]. Randomized trials have provided conflicting results when comparing proton 
pump inhibitor therapy and anti-reflux surgery in the long-term control of GERD symptoms 
[10,11]. However in recent years, an increasing volume of literature is being published 
concerning the potential long-term adverse effects of sustained proton pump inhibitor therapy 
use, including dementia, long-bone fractures and gastric adenocarcinoma [12 – 14].   
 
Previous publications have failed to demonstrate a clear consistent benefit of anti-reflux 
surgery in reducing the risk of esophageal adenocarcinoma compared to medical therapy 
[15,16]. However these publications have been limited by small sample sizes, with low numbers 
of esophageal adenocarcinoma in the long-term follow-up categories, and poorly defined 
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control populations specifically regarding severity of reflux [16]. The present study seeks to 
overcome the power limitations as the United Kingdom has the highest Incidence of esophageal 
adenocarcinoma globally. Furthermore, this study utilized two datasets to evaluate cancer risk 
following anti-reflux surgery, and also comparing high dose proton pump inhibitor therapy with 
anti-reflux surgery, and also evaluate a Barrett’s esophagus population.  
 
The primary objective of this study was to examine how anti-reflux surgery influences the risk 
of esophageal cancer in GERD patients. The secondary objectives were to evaluate esophageal 
cancer risk following anti-reflux surgery in Barrett’s esophagus patients and to provide a subset 
comparison of esophageal cancer risk for patients receiving standard-dose proton pump 
inhibitor therapy with anti-reflux surgery.   
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METHODS 
Design 
This was a national population-based cohort study of anti-reflux surgery conducted in England 
during the period 2000 to 2012 with follow-up until 2014. Anti-reflux surgery was the main 
exposure and esophageal cancer was the main outcome. Permissions for the comparison of 
anonymized administrative data were obtained from the National Information Governance 
Board for Health and Social Care in England. All procedural and diagnostic codes were 
independently verified at a local institutional level.   
 
Data sources and definitions  
Hospital Episode Statistics Database 
Data were derived from the Hospital Episode Statistics (HES) database [17]. This is a record-
based system that collects patient-level data from all National Health Service (NHS) hospitals in 
England. It captures all patients treated in public sector hospitals and all patients treated in 
privately funded institutions. Patients are given a unique HES identifier that allows all of their 
hospital admissions to be tracked.  The study population consisted of patients aged 18 years or 
older with a diagnosis of GERD as identified from the International Classification of Diseases 
version 10 (ICD-10) codes K210 and K219, and patients with Barrett’s esophagus using the ICD-
10 code K227. Patients receiving anti-reflux surgery were identified using the Office of 
Population Censuses and Surveys Classification of Surgical Operations and Procedures 4th 
revision (OPCS-4) codes; primary anti-reflux surgery (G242 – G245, G248 and G249) and 
revisional anti-reflux surgery (G251, G258, G259). Risk of esophageal cancer (ICD-10 codes C15 
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and D001) was compared between GERD and Barrett’s esophagus patients receiving anti-reflux 
surgery and those not receiving such surgery. Starting date was taken as the date of GERD 
diagnosis for both surgical and non-surgical groups.  
Because patients undergoing anti-reflux surgery will represent a group of patients with more 
severe GERD, a sensitivity analysis was performed by linking the HES with the Clinical Practice 
Research Datalink (CPRD) datasets to mitigate selection bias.  
 
Clinical Practice Research Datalink (CPRD) 
Almost 10% of the English population is registered with practices that enter data into the CPRD, 
formally the General Practice Research Database. About half of all CPRD practices are linked to 
in-patient HES data, which contain clinical information for each episode of care in English 
hospitals. Patient linkage was performed centrally using the National Health Service number. 
Database coverage was from 1997 to 2010, restricted by the end of cancer registry coverage. In 
CPRD, medcodes are based on the Read clinical coding system for primary care electronic 
health records developed in England. The study population consisted of patients aged 18 years 
or older with a diagnosis of GERD or Barrett’s esophagus were identified from CPRD data using 
the relevant Read codes or from the linked HES dataset using the ICD-10 codes described 
above. Patients undergoing anti-reflux surgery were identified using the relevant OPCS-4 codes 
described previously and were compared with patients receiving standard dose proton pump 
inhibitor therapy defined as at least 40mg of esomeprazole, omeprazole or pantoprazole or 
30mg of lansoprazole daily for at least one year. The CPRD dataset was linked to the National 
Cancer Registry, which permitted analysis of only esophageal adenocarcinoma in this subset 
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analysis. Risk of esophageal adenocarcinoma was compared among participants with GERD and 
Barrett’s esophagus separately receiving anti-reflux surgery and those receiving standard dose 
proton pump inhibitor therapy. Starting date was taken as the date of GERD diagnosis for both 
surgical and proton pump inhibitor treatment groups. 
 
Subset analyses 
Additional analyses were performed:  
(i) Comparison of esophageal cancer risk in patients aged 50 years or older receiving anti-reflux 
surgery vs. no anti-reflux surgery (HES dataset) or standard dose proton pump inhibitor therapy 
(CPRD dataset).   
(ii) Within the Barrett’s cohort, comparison of utilization of EMR or HALO following anti-reflux 
surgery vs. no anti-reflux surgery (HES dataset) or standard dose proton pump inhibitor therapy 
(CPRD dataset).  
(iii) Within the cohort of patients receiving anti-reflux surgery, analysis of esophageal 
adenocarcinoma risk in those patients within recurrent reflux (CPRD dataset). This was defined 
by the requirement standard dose proton pump inhibitor therapy at 6 months after surgery or 
for revisional anti-reflux surgery within the study period.  
 
Statistical analysis 
Categorical variables were expressed as percentages, with intergroup comparisons made using 
χ2 test, and continuous variables were expressed as medians and ranges, with intergroup 
comparisons made using Mann-Whitney U test. Cox proportional hazards models were fitted to 
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study the long-term esophageal cancer risk in England from both treatment groups. A 
multivariable model provided hazard ratios (HR) with 95% confidence intervals (CI), adjusted for 
age (18-29, 30-39, 40-49, 50-59, 60-69, 70-79, 80 years and older), sex (male or female), 
comorbidity (Charlson comorbidity index 0, 1 or ≥2) and obesity (yes or no). Obesity was 
defined using the ICD-10 code E66 (HES dataset) or a body mass index of 30kg/m2 within 6 
months of diagnosis of GERD (CPRD dataset). Inverse probability weights (IPW) were applied to 
correct for confounding and selection bias. Firstly, a logistic model was fitted to calculate the 
probability of having an anti-reflux surgery and the predicted values were used to calculate the 
inverse probability weights that were afterwards applied in the logistic models for esophageal 
cancer models. Survival curves were also obtained using the inverse probability weights [18]. 
Statistical analysis was performed using SPSS version 22.0 software (Statistical Package for the 
Social Sciences software, Version 22, SPSS Chicago (IL), USA) and using SAS version 9·4 (SAS 
Institute, Cary, NC, USA) and R 3.3.2 (R Foundation for Statistical Computing, Vienna, Austria).  
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RESULTS 
Hospital Episode Statistics analysis 
GERD patients aged 18 years or older receiving anti-reflux surgery vs. no such surgery 
Over the study period, 838,755 patients aged 18 years or older were diagnosed with GERD and 
included, of these 22,231 (2.7%) underwent anti-reflux surgery. Patients undergoing anti-reflux 
surgery were younger (median age 47 vs. 59 years; P<0.01), more commonly male (56% vs. 
52.3%; P<0.01) and obese (6.1% vs. 4.2%; P<0.01), and less commonly having Charlson score of 
≥2 (1.6% vs. 3.3%; P<0.01) (Table 1). The median follow-up period was 5.4 and 6.4 years in anti-
reflux surgery and non-surgery groups. Anti-reflux surgery was associated with a reduced risk of 
esophageal cancer (adjusted HR 0.64; 95% CI 0.52–0.78) (Table 2) (Figure 1).  
Barrett’s esophagus patients aged 18 years or older receiving anti-reflux surgery vs. no such 
surgery 
Over the study period, 28,372 patients aged 18 years or older were diagnosed with Barrett’s 
esophagus and were included, and 737 (2.6%) underwent anti-reflux surgery. Similar to the 
GERD cohort, patients with Barrett’s esophagus undergoing anti-reflux surgery were younger, 
more commonly obese and less commonly had Charlson score of ≥2 (Table 1). The median 
follow-up period was 5.6 and 4.9 years in anti-reflux surgery and non-surgery groups, 
respectively. Anti-reflux surgery was associated with decreased point estimates of esophageal 
cancer (adjusted HR 0.47; 95% CI 0.12–1.90) (Table 2) (Figure 2). 
Within the Barrett’s cohort the proportion of patients requiring EMR or HALO was similar 
following anti-reflux surgery (0.90%, 7 from 775 patients) compared with no anti-reflux surgery 
(1.59%, 439 from 27683 patients) (P=0.442).  
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Subset analysis: GERD patients aged 50 years or older receiving anti-reflux surgery vs. no such 
surgery  
Over the study period, 580,293 patients aged 50 years or older were diagnosed with GERD in 
HES. Of these, 9,753 patients (1.7%) underwent anti-reflux surgery. The median follow-up 
period was 5.4 and 6.4 years in anti-reflux surgery and non-surgery groups, respectively. Anti-
reflux surgery was associated with a reduced risk of esophageal cancer (adjusted HR 0.75; 95% 
CI 0.58–0.97) (Table 2).  
 
Subset analysis: Barrett’s esophagus patients aged 50 years or older receiving anti-reflux 
surgery vs. no such surgery 
Over the study period, 22,901 patients aged 50 years or older were diagnosed with Barrett’s 
esophagus. Of these 432 patients (1.9%) received anti-reflux surgery. The median follow-up 
period was 5.6 and 4.9 years in anti-reflux surgery and non-surgery groups, respectively.  Anti-
reflux surgery was associated with decreased point estimates of esophageal cancer (adjusted 
HR 0.76; 95% CI 0.19–3.09), but statistically non-significant (Table 2) (Figure 2).  
 
 
 
Clinical Practice Research Datalink analysis 
GERD patients aged 18 years or older receiving anti-reflux surgery vs. high-dose proton pump 
inhibitor therapy 
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16,938 patients aged over 18 years with GERD and on high dose proton pump inhibitor therapy 
were included in this analysis. From this cohort 1116 patients (6.6%) underwent anti-reflux 
surgery with the remaining 15,822 patients had proton pump inhibitor therapy alone. The 
median follow-up period was 5.2 and 5.3 years in anti-reflux surgery and high dose proton 
pump inhibitor therapy groups, respectively. Patients undergoing anti-reflux surgery were 
younger (median age 48 vs. 60 years; P<0.01), more commonly male (50.2% vs. 43.3%; P<0.01) 
and less commonly having Charlson score of ≥2 (9.1% vs. 20.9%; P<0.01), however there was no 
significant difference in the incidence of obesity between groups (2.1% vs. 2.5%; P=0.39). The 
prevalence of esophageal adenocarcinoma was decreased following anti-reflux surgery, but was 
not statistically significant (0% vs. 0.2%; P=0.16). No esophageal adenocarcinoma events were 
identified in the anti-reflux surgery cohort, which prevented the calculation of hazard ratios for 
this result.  
 
Barrett’s esophagus patients aged 18 years or older receiving anti-reflux surgery vs. high-dose 
proton pump inhibitor therapy 
Over the study period, 786 patients aged over 18 years with Barrett’s esophagus were included 
in this analysis. From this cohort 166 patients (21.1%) underwent anti-reflux surgery and 620 
patients (78.9%) were treated with high dose proton pump inhibitor treatment, of these 3 
(1.8%) and 18 (2.9%) patients were diagnosed with esophageal cancer during the study period, 
respectively. The median follow-up period was 5.8 years in both groups. Patients undergoing 
anti-reflux surgery were younger (median age 52 vs. 64 years; P<0.01), less commonly male 
(59.0% vs. 66.0%; P=0.10) and with Charlson score of ≥2 (9.0% vs. 19.4%; P<0.01), however 
  
14 
14 
there was no significant difference between the groups in the incidence of obesity (1.8% vs. 
1.1%; P=0.49). Anti-reflux surgery was followed by a decreased point estimate of esophageal 
adenocarcinoma, but this was not statistically significant (adjusted HR=0.75; 95% CI 0.21–2.63) 
(Figure 3).  
16 patients (2.0%) underwent HALO or EMR after the first recording of reflux or anti-reflux 
surgery. Of these two (1.2%) underwent anti-reflux surgery and the remaining 14 patients 
(2.3%) received standard dose proton pump inhibitor only (P=0.32).  
 
Subset analysis: GERD patients aged 50 years or older receiving anti-reflux surgery vs. high-dose 
proton pump inhibitor therapy 
11,727 patients aged over 50 years with GERD and on high dose proton pump inhibitor therapy 
were included in this analysis. From this cohort 518 patients (4.4%) underwent anti-reflux 
surgery with the remaining 11,209 patients had proton pump inhibitor therapy alone. The 
median follow-up period was 5.2 and 5.3 years in anti-reflux surgery and high dose proton 
pump inhibitor therapy groups, respectively. The prevalence of esophageal adenocarcinoma 
was decreased following anti-reflux surgery, but was not statistically significant (0% vs. 0.2%; 
P=0.26). No cancer events were identified in the anti-reflux surgery cohort, which prevented 
the calculation of hazard ratios for this result. 
 
Subset analysis: Barrett’s esophagus patients aged 50 years or older receiving anti-reflux 
surgery vs. high-dose proton pump inhibitor therapy 
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Over the study period, 622 patients aged over 50 years with Barrett’s esophagus were included 
in this analysis. From this cohort 92 patients (14.8%) underwent anti-reflux surgery and 530 
patients (85.2%) were treated with standard dose proton pump inhibitor treatment, of these 3 
(3.3%) and 18 (3.4%) patients were diagnosed with esophageal adenocarcinoma during the 
study period, respectively. The median follow-up period was 5.5 and 5.7 years in anti-reflux 
surgery and high dose proton pump inhibitor treatment groups, respectively. Anti-reflux 
surgery was followed by a decreased point estimate of esophageal adenocarcinoma, but this 
was not statistically significant (adjusted HR=0.77; 95% CI 0.21–2.78). 
 
Subset analysis; Patients with recurrent reflux following anti-reflux surgery 
From 2000 to 2010, 1116 patients underwent anti-reflux surgery, of which 335 (30.0%) were on 
proton pump inhibitor therapy six months after surgery and 51 (4.6%) underwent revisional 
anti-reflux surgery. No cancer events were noted in either group.  
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DISCUSSION 
This large population-based cohort study suggests that patients with GERD who undergo anti-
reflux surgery are at a reduced risk of esophageal cancer when compared to non-operated 
patients with GERD. Although limited by low statistical power, also when compared to GERD 
patients on proton pump inhibitor therapy, anti-reflux surgery suggested a decreased risk of 
esophageal cancer, and similar indications were found for patients with Barrett’s esophagus.  
 
The results of this study contradict some previous national population-based cohort studies, 
which showed that anti-reflux surgery does not consistently reduce the risk of esophageal 
adenocarcinoma compared to medical therapy in patients with GERD [19–21]. This might be a 
reflection of the large sample size studied and the relatively high incidence of esophageal 
cancer within the population studied, compared to previous publications. When considering the 
clinical implications of this study, the long-term adverse effects of proton pump inhibitor use 
must also be considered in patients with chronic GERD [12–14]. These adverse outcomes must 
be balanced against the short-term and long-term complications of anti-reflux surgery, 
although recent data does suggest that anti-reflux surgery is a very safe procedure with a 30-
day mortality rate of 0.03% [22]. The main analysis from the present study to demonstrate a 
statistically significant reduction in esophageal cancer risk was seen in the very large cohort 
including over 800,000 patients with over 20,000 patients receiving ARS. This does suggest the 
absolute reduction in esophageal cancer risk from anti-reflux surgery is small and requires a 
large number of patients to be studied in order to demonstrate any statistically significant 
reduction. In this study, patients with Barrett’s esophagus were also studied as a population at 
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increased risk of developing esophageal adenocarcinoma [23]. Although hampered by low 
precision, when GERD severity was accounted for by comparison of proton pump inhibitor 
therapy with anti-reflux surgery, there were similar reductions in the risk esophageal cancer 
associated with anti-reflux surgery, which again contradicts results from previous studies [24–
26].  
 
The mechanism of the reduced cancer risk seen with anti-reflux surgery when compared with 
non-surgical or medical treatment of GERD is multi-factorial. Anatomically anti-reflux surgery 
creates a barrier against the reflux of gastric contents into the lower end of the esophagus 
reducing the pro-inflammatory and carcinogenic process [27]. Medical treatment mainly does 
not mechanically prevent reflux, but does decrease the acidity of the refluxed content. 
Importantly, previous randomized controlled trials have showed a lower level of esophageal 
pathological acidity at 5-year followup after anti-reflux surgery compared with medication [28]. 
Also anti-reflux surgery is an intervention that is not dependent upon dose or compliance, 
which is a limitation of medical therapy for GERD.  
 
The population-based design with virtually complete inclusion of all eligible patients in England 
is strength of the study. The large sample size, complete follow-up of all patients, and the 
adjustment for several relevant confounding factors are other advantages. There are also 
limitations. The reliability of the methodology and accuracy of data collection is a limitation of 
most national administrative databases. From the national dataset utilized it was not possible 
to identify the diagnostic workup for GERD, including use of pH studies, which may have shown 
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heterogeneity across the country. Patients receiving anti-reflux surgery often have failed 
medical therapy and thus often have a more severe form of GERD, suggesting a potential 
selection bias of the HES analysis. However, this selection bias was reduced in the CPRD analysis 
comparing patients on proton pump inhibitor therapy with anti-reflux surgery. An additional 
subset analysis was also performed on patients aged 50 years and older to reduce any selection 
bias demonstrating similar findings, because younger patients maybe more likely to receive 
anti-reflux surgery [29]. Furthermore, although all analyses were adjusted for patient age, sex, 
obesity and comorbidity, there may have been unmeasured factors, that may have confounded 
the results. The incidence of esophageal cancer was low within the study cohort, but yet 
greater than previous publications in this field [16], because of the relatively high incidence of 
esophageal adenocarcinoma in England [4]. Yet, the statistical power was inadequate for the 
secondary analyses, documented by the wide confidence intervals. However, all analyses 
consistently indicated reduced risk of esophageal cancer in the anti-reflux surgery groups, 
indicating validity.  
 
In conclusion, the results of this national English population-based cohort study of patients with 
GERD, indicates that anti-reflux surgery is associated with a reduction in the risk of esophageal 
cancer. This reduction was suggested also in patients with Barrett’s esophagus undergoing anti-
reflux surgery. However, the absolute reduction is small and therefore patients should be 
counseled that anti-reflux surgery is primarily an operation for symptomatic relief from GERD. 
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FIGURES 
 
Figure 1: Kaplan Meier plot showing a reduction in freedom from esophageal cancer in GERD 
patients receiving no surgery (unexposed) compared with those receiving anti-reflux surgery 
(exposed) from HES database (HR=0.64; 95%CI 0.52–0.78; P-value:<0.01).  
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Figure 2: Kaplan Meier plot showing no significant difference in freedom from esophageal 
cancer in Barrett’s esophagus patients receiving anti-reflux surgery (exposed) vs. no surgery 
(unexposed) from HES database (HR=0.47; 95%CI 0.12–1.9; P-value: 0.29).  
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Figure 3: Kaplan Meier plot showing no significant difference in freedom from esophageal 
cancer in Barrett’s esophagus patients receiving anti-reflux surgery (exposed) vs. proton pump 
inhibitor treatment (unexposed) from CPRD database (HR=0.75; 95%CI 0.21–2.63).  
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TABLE 1. Comparison of Demographics Between Patients Aged 18 Years or Older Receiving 
Antireflux Surgery or Conservatively Managed With GERD or Barrett Esophagus 
 
TABLE 2. Unadjusted and Adjusted Risk of Esophageal Cancer Following Antireflux Surgery in 
Patients With GERD or Barrett Esophagus 
 
